Massachusetts Life Sciences Center’s Post

✨ NEWS SPOTLIGHT ✨ : "BRIGHT PEAK RAISES $90M SERIES C" Bright Peak Therapeutics, a company focused on developing immunotherapies, has raised $90 million in Series C funding from venture capitalists. The funding was led by Johnson & Johnson's strategic VC arm, JJDC, with participation from other investors. The company aims to develop immunotherapies to treat patients with cancer and autoimmune diseases. Bright Peak's lead drug candidate, BPT567, targets PD-1, stimulates IL-18 signals, and will treat certain tumor types if proven successful. The company plans to test BPT567 in a Phase 1/2a trial in solid tumors with roughly 100 patients. Bright Peak has raised over $197 million and plans to explore partnerships or an IPO to secure additional funding for its research. To access the full article, subscribe to SDBJ 👇 https://lnkd.in/gzmGrF28

Another oncology biotech has submitted its IPO plans. Pennsylvania startup ArriVent BioPharma, valued at $400 million, plans to list on Nasdaq to support its Phase III trial and prepare for commercialization. Its lead lung cancer drug is already marketed in China by Allist Pharmaceuticals. #arrivent #biotech #nasdaq #ipo #initialpublicoffering #drugdevelopment #oncology #oncologytrials #cancerresearch #wallstreet

🚀 Biotech Investments in May 2024: A Record-Breaking Month! 💰 Uniquity Bio, AltruBio Inc., and BridgeBio Oncology Therapeutics lead the pack in private biotech investments this May! With a whopping $300M, $225M, and $200M raised respectively, oncology and immunology dominate the funding scene. 🌟 North America secured the most funds, raising $2B across 21 rounds, followed by Europe and Asia-Pacific. These investments are fueling groundbreaking advancements in medical science. 🧬 Stay tuned for more updates on the biotech frontier! #Biotech #Investment #Innovation #Healthcare #MedTech

💰 Capital Raise   Amplia Therapeutics Limited (ASX:ATX) has today announced it is undertaking a fully underwritten Entitlement Offer to raise $4.27m. Under the Entitlement Offer, eligible shareholders will be able to subscribe for two (2) New Shares for every five (5) shares held.    Funds from this capital raise will be used to support Amplia’s ongoing Phase 2a ACCENT trial and undertake the Interim Analysis, produce additional narmafotinib and manufacture a further batch of 25,000 capsules, and support a pilot Investigator Initiated Trial in ovarian cancer.     For full details, read today’s ASX release 👉 https://lnkd.in/geu2NiAW     To view the Investor Presentation 👉 https://lnkd.in/g5KXUC8i     $ATX #pharma #biotech #pancreaticcancer #clinicaltrial #ovariancancer #cancer #capitalraise  

Join us for an enlightening conversation with Brian Fiske, who holds the distinguished positions of both Portfolio Member and Scientific Advisory Board Member at Alix Ventures, as he shares his expert insights on the evolving landscape of oncology care. #CancerTherapyInnovation #MythicTherapeutics #HealthcarePodcast #BiotechInsights

Sadly, cancer touches more and more people globally. 🏥 TILT Biotherapeutics Ltd, a Finnish biotech company, develops cancer immunotherapies with armed oncolytic viruses to destroy cancer cells. Since its establishment in 2013, TILT Biotherapeutics has raised more than EUR 60 million in financing, of which about EUR 45 million in venture capital. Health and life sciences is one of Tesi's strategic investment themes. That in mind, Tesi has participated in two of TILT's financing rounds – 2022 and 2024. Read more about the TILT and Tesi's role on its growth path in our case article! 👇 https://lnkd.in/dB4Q7-88 #VentureCapital #HealthandLifeSciences #BioTechnology

2023 Private Rounds by Therapeutic Area Private capital flow concentrated in early technology and Oncology/Immunology. This could have significant implications for available in-licensing volume in the medium term - Discovery platforms (mostly in Boston) have been the most attractive for capital raises this year - Oncology and Autoimmune target indications are mechanistic similar and account for almost 50% of all private capital placements in 2023 #biotechnology #funding #drugdevelopment

📣We are delighted to announce a strategic collaboration with CTI Clinical Trial and Consulting Services, a renowned full-spectrum research services provider, to bolster oncology-focused consulting services. This partnership combines decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space. Customers will benefit from the combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase global trials more rapidly and effectively. This alliance aims to determine the best and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of more oncology therapeutics to patients. Read the full release here ➡️https://hubs.la/Q02M2QsT0 #Biotech #Bioscience #Oncology #DrugDevelopment

Learn how Cullinan Oncology transitioned from R&D to the clinic and is now aiming to become a fully integrated commercial-stage biotech company. On this episode of Business of Biotech, CEO Nadim Ahmed shares his story and that of the company's drug discovery efforts, which have yielded multimodal candidates spanning a range of cancer indications. https://cytiva.link/6d9ma #Biotech #BusinessOfBiotech #DrugDiscovery

INOVIQ Ltd (ASX:IIQ) is pleased to announce that it has successfully completed an A$7 million placement to institutional and sophisticated investors at A$0.50 per share. Funds raised will be used to advance commercialisation of EXO-NET® research tools and SubB2M diagnostics, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics, enabling the Company to progress its pipeline and bring new products to market. Over the next 12-months, INOVIQ expects to achieve the following milestones: ◼ Revenue growth from sales of EXO-NET exosome isolation tools (through our Promega partnership and direct sales/services); ◼ Exosome diagnostic biomarker validation for ovarian cancer; ◼ Exosome diagnostic development agreement (collaborator/partner); ◼ Exosome therapeutic in vitro data for breast cancer; and ◼ Commercial partner for SubB2M test for monitoring breast cancer. To read the announcement go to: https://lnkd.in/gRSjY9mw To read the investor presentation go to: https://lnkd.in/gx-RWae7 #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Therapeutics #Diagnostics #CancerResearch #LifeSciences